TRI-AZA MACROCYCLES AND METAL COMPLEXES THEREOF

Abstract: Tri-aza macrocycles of formula (1), wherein m and n, which may be the same or different, is each zero or an integer 1, 2, or 3; p is zero or an integer 1 or 2; q is zero or an integer from 1 to 6 inclusive; R¹, R² and R³, which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, -CO₂H, -SO₃H, PO₃H₂ or aryl group; L is a covalent bond or linker group; Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group; and metal complexes and/or salts thereof are described together with processes for their prepar­ ation and compositions containing them. The compounds are useful for imaging and in the treatment of abnormal cell dis­ orders, such as in the treatment of tumours, and are particularly suitable for coupling to other molecules such as proteins for use in diagnosis and therapy.

Description: Field of the Invention This invention relates to functionalised tri-aza macrocycles, to metal complexes thereof, to conjugate compounds containing the functionalised tri-aza macrocycles and metal complexes thereof and to their use in diagnosis and therapy. Background to the Invention The attachment of metal ions to proteins, peptides and other, smaller molecules is a fast expanding technology, which has numerous proven and potential applications in research, in industry and, particularly, in medicine. In recent years, much of the impetus behind the development of this technology has been the ability to link metal ions to antibodies, especially monoclonal antibodies. Such metal labelled antibodies have found a widespread use, especially in medicine, where they have been employed, for example, to target the metal ion to a specific tissue type, both in vitro and in vivo . Thus, metal labelled antibodies have applications in locating specific tissue types (e.g. employing computer-aided tomographic techniques where the metal ion is in some way detectable) and in the treatment of cell disorders (e.g. treating mammalian tumours where the metal ion is a cytotoxic radionuclide). Conventionally, attachment of the metal ion to a protein such as an antibody has been achieved by complexation by an acyclic chelate such as a substituted diethylenetriaminepentaacetic acid [Gansow O. A. et al , Inorg. Chem., (1986), 25 , 2772] or ethylenediaminetetraacetic acid [Meares, C. F. et al , Acc. Chem. Res., (1984), 17 , 202] covalently linked to the antibody. Such acyclic complexes however tend to be unstable in vivo either as a result of acid-catalysed decomplexation or competitive chelate binding by Ca²⁺ or Zn²⁺ in serum, or as a result of competition from transferrin [Moerlein, S. M. et al , Int. J. Nuc. Med. Biol., (1981) 8 , 277]. The lack of stability can result in uncomplexed metal atoms in the body which have a cytotoxic effect on healthy tissue (e.g. bone marrow) or which markedly reduce the signal-to-noise ration of an imaging technique. A possible alternative to the use of acyclic chelates in the labelling of antibodies is the use of macrocyclic ligands, which has been suggested in broad terms [Gansow O.A. et al . Am. Chem. Soc. Symp. Ser., (1984), 241 , 215; UK Patent Specification Publication No. 2122641; and Moi M. K. et al , Anal. Biochem., (1985), 148 , 249-253]. We have found a new class of functionalised tri-aza macrocycles, members of which are able to form more kinetically inert complexes with metal ions than are chelating agents conventionally in use for the attachment of metal ions to proteins and other molecules. The macrocycles of the invention are particularly useful for attachment to proteins, especially antibodies, to provide conjugate compounds capable of binding metals to give complexes which are advantageously stable in vivo . Summary of the Invention Thus, according to one aspect of the present invention we provide a compound of formula (1): wherein R¹, R² and R³, which may be the same or different, is each a hydrogen atom or a C₁₋₆ alkyl, C₁₋₃alkoxyC₁₋₃alkyl, -CO₂H, -SO₃H, -PO₃H₂ or group (where R⁴ is a hydrogen atom, a C₁₋₆ alkyl or C₆₋₁₂ aryl group); L is a covalent bond or a linker group comprising an optionally substituted straight or branched C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene hydrocarbyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or a C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, C₅₋₈ cycloalkane, C₆₋₁₂ aromatic, or C₅₋₁₀ heteroaromatic groups, wherein the optional substituents are selected from fluorine, chlorine, bromine, or iodine atoms or groups selected from C₁₋₆alkoxy, hydroxy, nitro, -N(R⁶)(R⁷), [where R⁶ is a hydrogen atom or a C₁₋₆alkyl group and R⁷ is a C₁₋₆ alkyl group] and a group of formula -(CH₂) n CON(R⁸)(R⁹) [where n is zero or an integer 1 to 4 inclusive, R⁸ is a hydrogen atom or a C₁₋₆alkyl group, and R⁹ is a C₁₋₆ alkyl group optionally substituted by one or more halogen atoms, or nitro, amino or hydroxy groups; Z is a hydrogen atom or a reactive functional group capable of reaction with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group, with the proviso that when L is a covalent bond Z is said reactive functional group; and metal complexes and/or salts thereof. In the compounds of formula (1), alkyl groups represented by R¹, R² and R³ may be for example C₁₋₆alkyl groups such as methyl or ethyl groups. C₁₋₃AlkoxyC₁₋₃alkyl groups represented by R¹, R² or R³ may be for example methoxymethyl. R¹, R² or R³ may be for example a group of formula (where R⁴ is a hydrogen atom or a C₁₋₆alkyl, e.g. methyl, C₁₋₃ alkoxy₁₋₃alkyl, e.g. methoxymethyl, or C₆₋₁₂aryl, e.g. phenyl group). In general, compounds of formula (1) in which R¹, R² and R³ are the same are preferred. Compounds of this type in which R¹, R² and R³ are -SO₃H, -PO₃H₂, or, in particular, -CO₂H, are especially preferred. In the compounds of formula (1), it will be appreciated that the nature of the group L when it is a linker group may be varied widely without substantially affecting the usefulness of compounds of formula (1) and the metal complexes thereof. In the above definition, and in the same context whenever it appears below, the term "interrupted by" as applied to cycloaliphatic or aromatic groups is to be understood to also mean that these particular groups may additionally be present linked to the terminal carbon atom of the hydrocarbyl chain represented by L, at the opposite end of the chain to the carbon atom attached to the macrocycle. L may be an optionally substituted straight or branched C₁₋₂₀alkylene, C₂₋₂₀ alkenylene, or C₂₋₂₀ alkynylene chain, optionally interrupted by one or more -O- or -S- atoms or C₅₋₈cycloalkylene (e.g. cyclopentylene or cyclohexylene), C₆₋₁₂aromatic (e.g phenylene or substituted phenylene), C₅₋₁₀heteroaromatic (e.g furanyl, pyridyl), -N(R⁵)-, -CON(R⁵)- or -N(R)⁵CO- groups. Examples of substituents which may be present on the chain L include halogen atoms, e.g. fluorine, chlorine, bromine, or iodine atoms or groups selected from C₁₋₆alkoxy (e.g. methoxy or ethoxy), hydroxy, nitro, -N(R⁶)(R⁷), [where R⁶ is a hydrogen atoms or a C₁₋₆alkyl group and R⁷ is a C₁₋₆alkyl group; e.g. -NHCH₃ or -N(CH₃)₂], or substituted amido, e.g. a group of formula -(CH₂) n CON(R⁸)(R⁹) [where n is zero or an integer 1 to 4 inclusive, R⁸ is a hydrogen atom or a C₁₋₆alkyl group, e.g. methyl and R⁹ is an optionally substituted C₁₋₆alkyl group]. Substituted alkyl groups represented by R⁹ include for example C₁₋₆alkyl groups substituted by one or more halogen atoms, or nitro, amino or hydroxy groups. In general, in compounds of formula (1) the linker group is preferably an optionally substituted C₁₋₁₀alkylene, (especially C₁₋₆alkylene such as methylene, ethylene, propylene butylene, pentylene or hexylene) C₂₋₁₀ alkenylene or C₂₋₁₀ alkynylene chain optionally interrupted by one or more -O- or -S- atoms or cyclohexylene, phenylene, substituted phenylene, -NH-, -N(CH₃)-, -CONH-, -CON(CH₃)- -NHCO- or -N(CH₃)CO- groups. Particular examples of linker groups represented by L include, for example, -(CH₂) d - (where d is an integer 1 to 4 inclusive), -(CH₂) d NHCO(CH₂) e - (where e is an integer 1 to 4 inclusive) and -(CH₂) d NHCO(CH₂) e OCH₂-. The reactive functional group represented by Z in compounds of formula (1) may be any group capable of reacting with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group. Aromatic groups include, for example, phenolic groups. Heteroaromatic groups include for example imidazolyl groups. Thus, Z may be, for example, a halogen atom, for example a chlorine, bromine or iodine atom, or a group selected from -SH, -NH₂, hydrazine (-NHNH₂) or a derivation thereof, [for example-N(CH₃)NH₂, -NHCONHNH₂, -NHCSNHNH₂, or phenyl hydrazine], -NCO, -NCS, -COR¹⁰, [where R¹⁰ is a halogen atom such as a chlorine or bromine atom, or a N₃, C₁₋₆alkoxy, e.g. methoxy, C₆₋₁₂aryloxy (e.g. nitrophenyloxy or dinitrophenyloxy), imidyloxy (e.g. succinimidyloxy) or imidazolyoxy group], imide, e.g. maleimide, a vinyl group of formula -Het¹-C(Het²)=CH₂ (where Het¹ and Het², which may be the same or different, is each a nitrogen containing heterocyclic group, e.g. a pyridyl group or Het¹ is a nitrogen containing heterocyclic group and Het² is a hydrogen atom), for example a vinyl pyridyl group of formula especially or a dione of formula (where R¹¹ is a C₁₋₄ alkyl e.g. methyl, group). Metal complexes of the compounds of formula (1) include complexes wherein the metal is di- or tripositive and has a coordination number from 2 up to 6, especially 6. Examples of such metals include indium (In), gallium (Ga), cobalt (Co), copper (Cu), lead (Pb) and bismuth (Bi). In, Ga, Co and Cu are preferred, particularly In and Ga. In general the metal is preferably a radioactive isotope. Indium, especially ¹¹¹In, is particularly preferred. In general, optimum binding of the metal to the compounds of formula (1) may be achieved by selection of the ring size and where appropriate by adjusting the potential coordination number by choice of the group -(CH₂)R¹, -(CH₂)R², and/or -(CH₂)R³ In general, compounds of formula (1) in which -(CH₂)R¹, -(CH₂)R² and -(CH₂)R³ is each -CH₂CO₂H are particularly useful. Salts of the compounds of formula (1) include salts with bases, e.g. sodium or potassium salts, or acid addition salts such as hydrobromides or hydrochlorides. Pharmaceutically acceptable salts are particularly preferred. A particularly useful group of compounds of the invention has the formula (l) wherein R¹, R² and R³ are as defined for formula (1) and the groups -L and Z together represent a group (1) -(CH₂) r -X-Y [where r is zero or an integer from 1 to 6 inclusive, X is a group -NH-, (where R⁴ is a previously defined and s is zero or an integer 1 to 4 inclusive), -(CH₂) s NHNH-or -(OCH₂CH₂) t NH- (where t is an integer 1 to 6 inclusive) and Y is a group -COZ¹ or -CO(R)Z¹ (where R is a spacer group, and Z¹ is a group -(CH₂) t Hal (where Hal is a halogen atom), (where R¹² is a nitrogen containing aromatic heterocyclic group, for example a pyridyl group)], or (2) a group -(CH₂) r NCS; and the metal complexes and/or salts thereof. In compounds of this type, the spacer group R may be for example an alkylene, e.g. ethylene, alkoxyalkylene, e.g. methoxymethylene, aryl, e.g. phenylene, aralkylene, e.g. phenalkylene such as phenethylene, or cycloalkylalkylene, e.g. cyclohexylmethylene group. A further particularly useful group of compounds according to the invention has the formula (1) wherein R¹, R² and R³ are as defined for formula (1) and the groups L and Z together represent a group -(CH₂) r XH (where r and X are as defined above) and the metal complexes and/or salts thereof. Compounds of formula (1) in which L is a linker group [particularly those specifically identified for compounds of formula (1)] are especially useful. Z in compounds of formula (1) is preferably a reactive functional group, [particularly those specifically identified for compounds of formula (1)], especially a group of formula -Het¹-C(Het²)=CH₂ or a dione of formula Indium complexes of the compounds of formula (1) are particularly useful. The compounds of formula (1) and the metal complexes and/or salts thereof have a diagnostic use as imaging agents in vitro and in vivo . The compounds of formula (1) and the metal complexes and/or salts thereof are also cytotoxic agents and may be used in the treatment of abnormal cell disorders, for example in the treatment of tumours. For application of the compounds of formula (1) as imaging or cytotoxic agents, it is generally preferable to couple the compounds to other molecules such as proteins, especially antibodies, peptides or carbohydrates to form conjugate compounds, and the compounds of formula (1) are particularly well adapted for use in this respect. Thus, according to a further aspect of the invention, we provide a conjugate compound which comprises a compound of formula (1), or a metal complex and/or salt thereof, coupled to a protein, peptide or carbohydrate. The compound of formula (1) may be coupled through any thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group present in the protein, peptide or carbohydrate. In a preferred aspect of the invention, we provide a conjugate compound which comprises a compound of formula (1) or a metal complex and/or salt thereof, coupled to an antibody. It is to be understood that conjugate compound according to the invention may contain more than one molecule of a compound of formula (1) coupled to any one protein, peptide or carbohydrate molecule. In a particular aspect, the invention provides conjugate compound of formula (2) wherein R¹, R², R³, and L are as defined for formula (1): Z¹ is the residue of a reactive functional group as defined for formula (1); w is zero or an integer 1; z is an integer 1 or more; Ab is an antibody; and metal complexes and/or salts thereof. In particular, Z¹ may be for example -S-, -NH- -NHN=, -N(CH₃)N=, -NHCONHN=, -NHCSNHN=, -N(Ph)N= (where Ph is phenyl, -NC(O)-, -NC(S)-, -CO-, -Het¹―C(Het²)CH₂- or The antibody Ab in the conjugates of formula (2) may be a complete antibody molecule or a fragment thereof, or an analogue or either of these, provided that the antibody comprises of a specific binding region. Thus the antibody may be polyclonal, or, preferably, monoclonal, or a fragment thereof for example a Fab' or F(ab)₂' fragment. If desired the antibody may be a recombinant antibody, (i.e. an antibody which has been produced using recombinant DNA techniques). The antibody may be a chimaeric antibody comprising linked antibody fragments, each from a different source (see for example International Patent Specification No. WO 86/01533). The antibody may be specific for any number of antigenic determinants, but is preferably specific for one antigenic determinant. Particular determinants include tumour cell-associated antigens, particularly mammalian tumour cell antigens for example oncofetal antigens such as carcinoembryonic antigen or alphafetoprotein. A particular useful antibody is that known as B72.3 [Colcher D. et al Proc. Nat. Acad. Sci. USA (1981), 78 , 3199]. The antibody Ab will in general be coupled to the remainder of the conjugate of formula (2) (i.e. the macrocycle and linker) through any appropriate reactive atom or group, for example a nitrogen or, especially, sulphur atom, present in the antibody. It will be appreciated that any one antibody molecule may contain more than one reactive group capable of coupling with the macrocycle and linker. Thus, for example, z in the conjugates of formula (2) may be an integer 1, 2, 3, 4, 5, 6 or more depending on the number of macrocycles linked to any particular antibody molecule or fragment or analogue thereof. Indium complexes of conjugates of formula (2) are particularly useful. It is to be understood that the definitions and preferences expressed for R¹, R², R³ and L in compounds of formula (1), and for classes of compounds of formula (1) are also applicable to conjugates of formula (2). Particularly useful conjugate compounds according to the invention are those comprising a compound of formula (1a), or a metal complex and/or salt thereof, coupled to an antibody. The indium complexes of these conjugates are especially important. The compounds of formulae (1) and (2) may be formulated for use in accordance with conventional practice, and thus according to a further aspect of the invention we provide a composition comprising a compound of formula (1) or a compound of formula (2) or a metal complex and/or salt thereof, together with one or more pharmaceutically acceptable carriers. Particularly suitable compositions according to the invention are those adapted for parenteral administration, especially intravenous administration. Suitable formulations of this type include solutions of the compounds of formulae (1) or (2) in isotonic saline. The quantities of compounds of formulae (1) or (2) used in formulations according to the invention will vary according to the intended use (i.e. imaging or therapy) and other variables such as the intended cell target, but may be easily determined in accordance with conventional practice for reagents of this type. Compounds of the invention may be prepared by the following processes wherein the groups and symbols R¹, R², R³, L, Z, Ab and z are as defined for formulae (1) and (2) except where stated otherwise. Where a metal complex is desired as a final product, the complexation with a metal atom may be carried out as a final step in the production process, as described below for the complexation of compounds of formulae (1), or alternatively it may be desirable to complex the metal at an earlier stage in the process, providing of course that the requisite macrocycle structure is present. In the following processes, it may be desirable to use starting materials in which the group Z is in a protected state, or which contain a precursor of the group, as discussed below. Thus, according to a further aspect of the invention a compound of formula (1) or a metal complex thereof may be prepared by reaction of a corresponding compound of formula (3) or a metal complex thereof, with a reagent R¹(CH₂)D (where D is a displaceable group). Displaceable groups represented by D include for example halogen atoms, for example a bromine, chlorine or iodine atom. The reaction may be performed in a solvent such as water or an organic solvent such as a nitrile e.g. acetonitrile or an alcohol e.g. isopropanol or an amide e.g. dimethylformamide in the presence of a base, e.g. an inorganic base such as an alkali metal carbonate or hydroxide, e.g. sodium, potassium or caesium carbonate, or sodium, potassium or lithium hydroxide, at a high temperature e.g. the reflux temperature. In this reaction, the group Z may need to be in a protected state. Conventional protecting groups may be used, depending on the nature of Z, and may be removed using standard procedures, once the desired reaction has been effected. Similarly, when the reagent R¹(CH₂)D contains an acid group this may also need to be protected, for example as an ester e.g. a methyl ester. The acid may be re-generated after the desired reaction is complete, for example by hydrolysis using an acid such as sulphuric acid. It will be appreciated that where it is desired to prepare a compound of formula (1) in which R¹, R² and R³ are not the same this may be achieved by first selectively N-protecting the compound of formula (3) or a precursor using an appropriate amine protecting group(s), for example a p-toluenesulphonyl group as described below, in accordance with conventional practice. Reaction of the N-protected compound (3) with R¹(CH₂)D followed by deprotection and further reaction as necessary with other reagents R¹(CH₂)D then yields the desired compound in which R¹, R² and R³ are not the same. Where metal complexes of compounds of formulae (1) or (2) are required (or any other suitable macrocyclic intermediate described herein) these may be prepared by treating the compound with a metal salt (for example a metal halide) in an appropriate solvent for example an aqueous or non aqueous solvent, (e.g. acetonitrile, acetone, propylene carbonate, dimethylformamide or dimethylsulphoxide) at any suitable temperature from 0°C to 100°C such as 10° to 80°C e.g. around 60°C. In another process, a compound of formula (1) or a metal complex thereof wherein R¹, R² and R³ is each -(CH₂)PO₃H₂ (where q is an integer 1 to 6) may be prepared by reaction of a compound of formula (3) or a metal complex thereof with phosphorous acid and an aldehyde R b CHO (where R b is a C₁alkyl group) in the presence of an acid, such as hydrochloric acid at an elevated temperature, e.g. 100°-130°C. Compounds of formula (1) may also be prepared by interconversion from other compounds of formula (1). Thus one functional group Z may be exchanged for another and, if desired a linker group L changed to another by appropriate manipulative reactions. For example, a compound of formula (1) where -L-Z is a group -L¹-NHCO-L²-Z (where -L¹-NHCO-L² represents the group L) may be prepared by reaction of a corresponding compound wherein -L-Z represents -L¹-NH₂ with a reagent R b O-L²-Z (where R b is for example an imide, such as succinimide, or a substituted phenyl group such as a p-nitrophenyl group) in the presence of a tertiary amine, such as diisopropylethylamine, in a solvent such as dimethylformamide. Reagents of formula R b O-L²-Z are either known compounds or may be obtained form known starting materials using methods analogous to those used for the preparation of the known compounds. A conjugate compound of formula (2) or a metal complex thereof may be prepared by reaction of a corresponding compound of formula (1) or a metal complex thereof with an antibody Ab (as previously defined). The reaction may be performed in a suitable solvent, for example an aqueous solvent such as a phosphate buffer, at an appropriate temperature, for example at 0°-30°C, especially 0°-10°C e.g 4°C. The antibody Ab may be obtained using procedures well known in the art. If desired, before the coupling reaction, the antibody may first be treated to yield appropriate groups for reaction with the compound of formula (1). Thus for example the antibody may be subjected to oxidation, for example periodate oxidation to yield aldehyde groups, or, in particular, may be treated with a reagent [e.g. Traut's reagent (2-iminothiolane)] using standard procedures to generate free sulphydryl groups in the molecule. Salts of compounds of formulae (1) or (2) and their metal complexes may be prepared by conventional means, for example by reaction with an appropriate base or acid in a suitable aqueous solvent. It will be appreciated that in reactions to obtain an intermediate of formula (3) the group Z may need to be in a protected form. Alternatively a precursor of the group may be used. For example where Z is an amino group, the amino function may be generated from a corresponding nitrile during the reduction of a diamide of formula (6). The starting material for this reaction may be prepared from a compound of formula (6), in which Z is a nitrile group, as described previously. The intermediate compounds of formula (3) are novel and form further aspects of the invention. Intermediates of formula (3) may be prepared by deprotection of a compound of formula (7) (where p is as just defined, R¹³ is a nitrogen protecting group such as a p-toluenesulphonyl group and -L-Z is as defined previously). The deprotection will depend on the nature of the protecting group R¹³. Thus, for example, when R¹³ is a p-toluenesulphonyl group removal of this may be achieved by treatment of the compound of formula (7) with an acid, for example HBr-acetic acid, in the presence of phenol at a high temperature, or by reaction with lithium in liquid ammonia in the presence of an alcohol such as ethanol. Intermediates of formula (7) may be prepared by treating a compound of formula (8) R¹³NHCH₂CH(L-Z)N(R¹³)CH₂(CH₂)NHR¹³ (8) with a compound R¹³OCH₂(CH₂)OR¹³ in the presence of a base such as caesium carbonate in a solvent such as dimethylformamide. Intermediates of formula (8) may be prepared by reduction of compounds of formula (9) H₂NCOCH(L-Z)NHCO(CH₂)NHR¹³ (9) using for example borane as described above with intermediates of formula (4), followed by protection using a suitable protecting agent, for example p-toluenesulphonyl chloride (e.g. by reaction with p-toluenesulphonyl chloride in a solvent such as dichloromethane in the presence of a base such as triethylamine at e.g. reflux). Intermediates of formula (9) may be prepared by reacting an appropriate substituted amino acid of formula (10) R¹¹O₂CCH(L-Z)NH₂ (10) (where R¹¹ is a previously defined) with a reagent HalOC(CH₂) m NHR¹³ (where Hal is a halogen atom) in the presence of a base such as triethylamine, followed by reaction with ammonia in a solvent such as methanol. The intermediates of formula (10) are either known compounds or may be prepared by methods analogous to those used for the preparation of the known compounds. In an alternative process, intermediates of formula (7) may be prepared by reaction of a compound of formula (11) R¹³HNCH(L-Z)CH₂N(R¹³)CH₂(CH₂)NHR¹³ (11) with a compound R¹³OCH₂(CH₂)OR¹³ in the presence of a base such as caesium carbonate in a solvent such as dimethylformamide. Intermediates of formula (11) may be prepared by reduction of compounds of formula (12) H₂NCH(L-Z)CONHCH₂(CH₂)NHR¹³ (12) using for example borane as described above, followed by reaction to introduce the protecting group R¹³, for example with p-toluenesulphonyl chloride as described previously. Intermediates of formula (12) may be prepared by reaction of an appropriately substituted amino acid of formula (13) H₂NCH(L-Z)CO₂R¹⁴ (13) (where R¹⁴ is as defined above with a diamine H₂NCH₂(CH₂)NH₂ at a high temperature, e.g. the reflux temperature. Amino acids of formula (13) are either known compounds or may be prepared by methods analogous to those used for the preparation of the known compounds. The invention is illustrated by the following Examples. Description of Specific Embodiments Intermediate 1 3-para-Cyanobenzyl-1,5,9-triaza-2,4-dioxocyclododecane To a solution of p-cyanobenzyldiethyl malonate (5.50g) in dry ethanol (500ml) was added 1,7-diamino-4-aza-heptane (2.62g) and the mixture was refluxed for 5 days. After evaporation of solvent, the residue was chromatographed on silica [eluting with 1% NH₄OH, 40% methanol, 59% CH₂Cl₂] to yield the title compound as a colourless solid (990mg) m.p. 263-265°C m/e (chemical ionisation, NH₃) 315 (M⁺+1), 316 (M⁺+2); δ H (CDCl₃) 7.53 (2H,d), 7.50(2H, br N H CO), 7.34 (2H, d), 3.65 (2H, mult.) 3.34 (2H,d), 3.23 (1H, mult.), 3.21 (2H, d), 2.9-2.8 (2H, mult.), 2.68 (2H, mult.) 1.73 (2H, mult.), 1.56 (2H+1H, mult.). Intermediate 2 3-para-Cyanobenzyl-1,5,9-triaza-5-p-toleunesulphonyl-2,4-dioxocyclododecane To a suspension of Intermediate 1 (628mg) in dichloromethane (20ml), was added triethylamine (200mg) and p-toluenesulphonyl chloride (381mg) and the mixture was heated at reflux for 18h. After filtration, the residue was chromatographed on silica (CH₂Cl₂-methanol) to yield the title compound as a colourless foam (749mg) m/e [desorption chemical ionisation (NH₃)] 469 (M⁺+1), 468, 289, 255, 215, 157, i.r. (KBr), 3300 (NH), 2215 (CN), 1670, 1640, 1530 (br.s.), 1160cm⁻¹ δ H (CD₃OD), 7.74 (2H,d), 7.65 (2H,d), 7.43 (4H, mult.), 3.49-3.11 (9H,m.), 2.91-2.82 (2H,m), 2.47 (3H,s), 1.74 (2H,m), 1.60 (2H,m). Intermediate 3 3-para-Aminomethylbenzyl-1,5,9-triaza-5-tosyl-cyclododecane To a suspension of Intermediate 2 (468mg) was added 1M borane-tetrahydrofuran solution (20ml) and the mixture was refluxed for 36h. Excess borane was destroyed by slow addition of methanol (5ml) and solvents were removed under reduced pressure to yield a residue which was treated with 6M HCl (15ml) and refluxed for 3h. After removal of water, the residue was taken up in the minimum volume of 2M KOH solution and extracted with chloroform (3 x 20ml). Removal of solvent geve the title compound as a colourless oil (400mg). m/e (chemical ionisation, NH₃) 446 (M⁺+2), 445 (M⁺+1), 324, 289, 229, δ H (CDCl₃) 7.67 (2H,d), 7.29 (2H,d), 7.23 (2H,d), 7.11 (2H,d), 3.83 (2H,s), 3.27-3.16 (4H,m), 2.86-2.77 (4H,m), 2.62-2.52 (4H,m), 2.48-2.45 (2H,d), 2.42 (3H,s), 2.17-1.91 (4H,m), 1.78-1.68 (4H,m), δ c (CDCl₃), 143.2, 129.6, 129.0, 127.4, 127.1, 51.8, 46.1, 45.9, 45.2, 38.3, 37.7, 26.6, 21.5, i.r. (Nujol) 3300 (NH), 1590, 1160cm⁻¹. Intermediate 4 3-para-Aminomethylbenzyl-1,5,9-triazacyclododecane tetrahydrobromide To a solution of Intermediate 3 (400mg) in HBr-acetic acid (45%, 25ml) was added phenol (0.5g) and the mixture was heated at 110°C for 36h. After cooling a colourless solid was filtered, washed with acetone and dried (K₂CO₃) to yield the title compound , (525mg) i.r. (KBr) 3600-3300 (br,NH), 2890,1585cm⁻¹ δ H (D₂O) 7.11 (2H,d), 7.06 (2H,d), 3.79 (2H,s), 3.13-2.78 (12H,m), 2.56 (2H,d), 2.29 (1H,m), 1.81-1.69 (4H,m). Intermediate 5 3-para-Acetamidomethylbenzyl-1,5,9-triazacyclododecane To an aqueous solution of Intermediate 4 (525mg pH6.8, 5ml) was added a solution of p-nitrophenylacetate (543mg) in dioxan (5ml) and the mixture was stirred at 35°C for 18h. After washing with ether (3 x 10ml) the pH of the solution was raised to 13.5, and the solution extracted with chloroform (5 x 10ml), dried (K₂CO₃), filtered and evaporated to give the title compound as a colourless oil (228mg), m/e (chemical ionisation, NH₃) 334 (M⁺+2), 333 (M⁺+1). δ H (CDCl₃) 7.25 (2H,d), 7.16 (2H,d) 4.39 (2H,d), 3.48 (2H,s), 2.87-2.53 (14H,m) 2.17 (1H,m), 2.02 (3H,s) 1.85-1.40 (7H,m). Intermediate 6 3-para-Acetamidomethylbenzyl-N,N′,N″-tricarboethoxymethyl-1,5,9-triazacyclododecane To a solution of Intermediate 5 (166mg) in dry acetonitrile (5ml) was added anhydrous sodium carbonate (170mg) and ethyl bromoacetate (251mg) and the mixture refluxed for 18h. After filtration and removal of solvent, the residue was chromatographed on neutral alumina (activity II/III, 3% methanol/CH₂Cl₂) to yield the title compound as a colourless gum (59mg) m/e (chemical ionisation, NH₃) found 590.372253 (calculated 590.3679504) 591 (M⁺+1), 590 (M⁺) 547, 503, 428, i.r. (liquid film) 3280 (NHCO), 2920, 1735, 1660cm⁻¹. δ H (CDCl₃) 7.16 (4H,m), 5.80 (1H,m), 4.39 (2H,d), 4.13 (6H,q), 3.23 (4H,s), 3.19 (2H,s), 2.85-2.53 (8H,m), 2.45-2.23 (7H,m), 2.02 (3H,s), 1.78-1.60 (4H,m), 1.29-1.23 (6H, + 3H,t+t). Intermediate 7 2,6-Diamino-1-hexanoic acid, ethylenediamine ester 2,6-Diamino-1-hexanoic acid, methyl ester, dihydrochloride (10.283g) was added (as solid) in small batches over a 50 minute period to ethylenediamine (100ml) at 90°C, with stirring. The temperature of the reaction mixture was then raised to 140°C for 6hrs, after which the ethylenediamine was removed by vacuum distillation to yield a brown residual oil which was taken up in 4M NaOH (25ml) and dried in vacuo . Methanol (30ml) was added, the solution was filtered, the methanol removed (Buchi) and the residue dissolved in CH₂Cl₂ (100ml), then filtered, and the filtrate rotovated down to give the title compound as a clear brown oil (8.827g). i.r. (thin film) 3300/3280 3060 2930 2860 1650 1570 1470 1320cm⁻¹. Intermediate 8 1,5,9-Triamino-3-aza-nonane, tetrahydrochloride Intermediate 7 (3.754g) and borane-tetrahydrofuran (130mmol, 130ml) was refluxed for 21 hours. After removal of volatiles, the aminoborane was washed with methanol (2 x 100ml) and hydrolysed with 6M HCl (150ml, 110°C) for 3 hours. The resulting solution was evaporated, methanol (20ml) added and further evporated to yield the title compound (6.279g) as a white hygroscopic solid. Intermediate 9 1,5-Diamino-(9-N-benzamidyl)1-3-aza-nonane Intermediate 8 (6.16g) and potassium hydroxide (4.4g) was dissolved in water (50ml) and, with stirring, copper carbonate (2.603g) was added. Continued stirring over 30 minutes at 50°C yielded an intense blue solution which was cooled to 0°C and benzoyl chloride 2.5ml added in 0.25ml portions over 90 minutes keeping the pH greater than 9 with periodic addition of KOH pellets. The solution was then allowed to stir at room temperature for 1 hour, then filtered and the filtrate treated with H₂S over 30 minutes. The solution was filtered once again to give a greeny-yellow filtrate which on addition of KOH to pH14 went a dark green, with a small amount of green precipitate. This was filtered off, the filtrate reduced in volume to 40ml and exhaustively extracted (13x) with CH₂Cl₂, dried (K₂CO₃), and evaporated to yield the title compound as a pale yellow oil (2.152g). ¹H-NMR (250MHz), δ(CDCl₃): 1.57 (m, 16H, CH₂, NH, NH₂) 2.37 (dd, 1H, CH), 2.67 (m 3H, CH₂N), 2.79(m, 3H, CH₂N). Intermediate 10 1,5-Ditosylamino-3-tosyl-(9-N-benzamidyl)-3-aza-nonane Intermediate 9 (1.978g) in dry CH₂Cl₂ (50ml) was added dropwise to a solution of tosyl chloride (5.087g), in dry CH₂Cl₂ (50ml) and the mixture was then allowed to stir for 2 1/2 hours at room temperature. The solution was then washed with water (20ml) dried (K₂CO₃), filtered and evaporated to an oily brown residue which was redissolved in CH₂Cl₂ (10ml). After a few minutes a white solid precipitated which was collected by filtration and washed with CH₂Cl₂ to give the title compound (1.701g). TLC (silica; 5% methanol in CH₂Cl₂) Rf 0.44 m/e [desorption chemical ionisation (methanol)] 741 (M⁺+1), 740 (M⁺). Intermediate 11 2-(4-N-Benzamidyl)butyl-N,N′,N″-tritosyl-1,4,7-triazacyclononane Intermediate 10 (3.70g) was dissolved in anhydrous dimethylformamide (200ml) and caesium carbonate (3.26g) added under dry nitrogen. A solution of ethylene glycol ditosylate (1.85g), in anhydrous dimethylformamide (50ml) was slowly added, with stirring, over 4 hours. Stirring was continued overnight (20°C) and the temperature then raised to 65°C for 3 hours. The dimethylformamide was removed under reduced pressure and the residue dissolved in chloroform (200ml), washed with water (3 x 30ml) and dried (K₂CO₃). The residue was dissolved in the minimum volume of CH₂Cl₂ (15ml) and ethanol added slowly until turbidity. The flask was chilled to -20°C overnight and the title compound (2.6g) separated as a colourless solid. m/e [desorption chemical ionisation (CHCl₃)] : 767(M⁺+1), 766 (M⁺) (100%). Intermediate 12 2-(4-N-Benzamidyl)butyl-1,4,7-triazacyclononane To Intermediate 11 (1.2g) in a flask under nitrogen was added ethanol (2ml), and liquid ammonia (100ml) then allowed to condense in the flask. Lithium metal (0.38g) was added and an intense blue colour developed which discharged within 20 minutes. After evaporation of NH₃ (4 hours) water (20ml) was added and the solution evaporated to dryness, taken up in 6 MHCl (20ml) washed with ether (3 x 20ml), evaporated to dryness and redissolved in 6M KOH (20ml) and extracted with dichloromethane (5 x 20ml). The extract was dried and evaporated to yield the title compound (360mg). m/e [desorption chemical ionisation (methanol)]: 305 (M⁺+1) Example 1 3-para-Aminomethylbenzyl-1,5,9-triazacyclododecane-N,N′N″-triacetic acid Intermediate 6 (59mg) was added to 6M HCl (5ml), and refluxed at 110°C for 18 hours, to yield the title compound following romoval of volatiles. The title compound was homogeneous by cation-exchange hplc, (Synchropak TSK DEAE, ammonium acetate (pH7), CH₃CN). m/e (FAB, glycerol) 465 (M⁺+1), 464 (M⁺). Example 2 (a) The compound of Example 1 (2.6mg) in 0.5M 1,4-piperazine bis(ethanesulphonic acid) [PIPES; pH6.8, 300µl] was added to the sulphite salt of the n-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl) maleimide [Yamada et al , Eur. J. Biochem., (1979). 101 , 395; 10mg] in 1,4-dioxan (300ml). The reaction was monitored by high performance liquid chromatography (hplc) using a polymer reverse phase column (PLRP, 100Å, 15cm x 4.4mm internal diameter) using the following conditions: TIME %A %B %C 0 87 10 3 20 40 10 50 20.1 87 10 3 A = H₂O, B = 1M ammonium acetate pH6.5, C = CH₃CN. λ = 268nm, Flow rate = 1.0ml/min. The desired product eluted at 19 minutes and was purified preparatively to give a solution (approximately 5ml, 500µM) of a compound of formula (1) wherein m is 2, n is 2, p is 1, -(CH₂) q R¹, -(CH₂) q R² and -(CH₂) q R³ is each -CH₂CO₂H, and -L-Z is a group (b) The solution prepared in 2(a) was adjusted to pH5 using acetic acid/water (25%v/v) and to 90µl of this was added ¹¹¹InCl₃ (10µl, 112µCi) and the reaction left at 55°C for 1 hour. The mixture was then purified by hplc using the above programme and radiometric detection. The ¹¹¹In complex of the compound of formula (1) described above eluted at 18 minutes and was collected and concentrated to a low volume (approximately 100µl). (c) B72.3 monoclonal antibody [Colcher, D. et al Proc. Nat. Acad. Sci. USA (1981), 78 , 3199; 1.2mg, previously modified with Traut's reagent to liberate 5.7 thiols/antibody] in 0.3M phosphate buffer (containing 2mM ethylenediaminetetraacetic acid; pH8.0; 110µl) was added to the ¹¹¹In complex prepared in 2(b) and the mixture was incubated at 4°C overnight then purified by PD-10 gel filtration chromatography to yield the ¹¹¹In complex of the conjugate of formula (2) wherein m is 2, n is 2, p is 1, -(CH₂) q R¹, -(CH₂) q R² and -(CH₂) q R³ is each -CH₂CO₂H, L-Z¹ is z is an integer 1 or more and Ab is a B72.3 monoclonal antibody. The conjugate was injected in mice and the tissue distribution of the ¹¹¹In determined after 4 hours and 24 hours. The results are as shown in Table 1. Tissue 4 Hours 24 Hours %Dose/g Tissue % Total Injected Dose % Dose/g Tissue % Total Injected Dose Blood 32.4 60.9 21.275 47.52 Kidneys 12.32 2.88 8.92 2.495 Liver 8.605 12.36 6.555 9.955 Lungs 15.16 2.215 9.315 1.45 Spleen 6.075 0.41 6.44 0.53 Stomach - 0.7 - 0.645 Small Intestine - 2.39 - 2.6 Large Intestine - 2.935 - 2.175 In control experiments using free ¹¹¹In and ¹¹¹In bound to macrocycle only, all radioactivity was cleared from the tissues in a few hours. The persistence of ¹¹¹In the tissues after 24 hours as shown in Table 1 illustrates that the indium complex described in 2(c) has been bound by the antibody. Example 3 2-O-(6-ethenyl)-2-(pyridyl)methyl-N-[4-(2-perhydro-1,4,7-triaxaninine-1,4,7-tri(2-acetic acid)butyl)ethanamide]. (a) 2-(4-N-Benzamidyl)butylperhydro-1,4,7-triazanonine-1,4,7-tri(2-acetic acid) Lithium hydroxide monohydrate (14.5mg) and 2-bromoacetic acid (31.0mg) were added to Intermediate 12 (20mg) in water (0.476ml), the pH being kept at pH12 and above using additional lithium hydroxide as necessary. The solution was heated to 80°C and the reaction monitored by reverse phase high performance liquid chromatography using Lys1 and the following programme: BUFFERS: A = 0.1% trifluoroacetic acid/H₂O B = 0.1% trifluoroacetic acid/CH₃CN λ = 254nm; flow = 1.4ml/minute Time (T; min) %A %B 0 95 5 20 5 95 25 5 95 Equilibration time = 10 minutes. During the reaction a major peak built up within 30 minutes at T = 11.43 with a minor peak at T=12.077. The major peak was assumed to be the dicarboxylated species and further additions of acid were therefore made to the reaction solution over a 24 hour period to maximise the yield of the produce at T = 12.077. After 24 hours the reaction solution was subjected to preparative high performance liquid chromatography using Lys 1 to yield the title compound (100.9mg) of Part (a). m/e 479 (M⁺+1). (b) 2-(4-Amino)butylperhydro-1,4,7-triazanonine-1,4,7-tri(2-acetic acid) The compound of Part (a) [5mg] was dissolved in 6M HCl (3ml) and heated at 130°C under nitrogen for 18 hours. The solution was dried in vacuo and the residue redissolved in dry dimethylformamide. The drying and redissolving in dimethylformamide was repeated three times to yield the title compound of Part(b) which was used in the following reaction without further purification. 2-O-(6-ethenyl)-2-(pyridyl)methyl-N-[4-(2-perhydro-1,4,7-triazanonine-1,4,7-tri(2-acetic acid)butyl)ethanamide] (c) The p-nitrophenyl ester of 2-vinyl, 6-methoxyacetic acid pyridine (3.0mg) in dry dimethylformamide (0.5ml) was added to the amine prepared in Part (b) above, followed by diisopropylethylamine (9.0mg). The reaction was monitored by reverse phase high performance liquid chromatography using Lys1 and the programme described in Part(a) above. The product which was observed at T=10.5min was collected and lyophillised to give the title compound [3.0mg] m/e (FAB, glycerol) 550 (M⁺+1). The title compound elutes at T=8.10 on anion exchange chromatography (Synchropak AX101) using the following programme:

Claims: A compound of formula (1): wherein R¹, R² and R³, which may be the same or different, is each a hydrogen atom or a C₁₋₆ alkyl, C₁₋₃alkoxyC₁₋₃alkyl, -CO₂H, -SO₃H, -PO₃H₂ or group (where R⁴ is a hydrogen atom, a C₁₋₆ alkyl or C₆₋₁₂ aryl group); L is a covalent bond or a linker group comprising an optionally substituted straight or branched C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene hydrocarbyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or a C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, C₅₋₈ cycloalkane, C₆₋₁₂ aromatic, or C₅₋₁₀ heteroaromatic groups, wherein the optional substituents are selected from fluorine, chlorine, bromine, or iodine atoms or groups selected from C₁₋₆alkoxy, hydroxy, nitro, -N(R⁶)(R⁷), [where R⁶ is a hydrogen atom or a C₁₋₆alkyl group and R⁷ is a C₁₋₆ alkyl group] and a group of formula -(CH₂) n CON(R⁸)(R⁹) [where n is zero or an integer 1 to 4 inclusive, R⁸ is a hydrogen atom or a C₁₋₆alkyl group, and R⁹ is a C₁₋₆ alkyl group optionally substituted by one or more halogen atoms, or nitro, amino or hydroxy groups; Z is a hydrogen atom or a reactive functional group capable of reaction with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group, with the proviso that when L is a covalent bond Z is said reactive functional group; and metal complexes and/or salts thereof. A compound according to claim 1 wherein R¹, R², and R³ is each a -CO₂H group. A compound according to claim 1 or 2 wherein Z is a halogen atom or a group selected from -SH, -NH₂, hydrazine or a derivative thereof, -NCO, -NCS, -COR¹⁰ (where R¹⁰ is a halogen atom or a N₃, C₁₋₆ alkoxy, C₆₋₁₂ aryloxy, imidyloxy or imidazolyloxy group), imide, -Het¹-C(Het²)=CH₂ (where Het¹ and Het² which may be the same or different, is each a nitrogen containing heterocyclic group, or Het¹ is a nitrogen containing heterocyclic group and Het² is a hydrogen atom) or a dione of formula (where R¹¹ is a C₁₋₄ alkyl group). A metal complex of a compound of formula (1) as defined in any of the preceding claims wherein the metal is indium or gallium. An indium complex of a compound of formula (1) as defined in claims 1 to 3. A conjugate compound which comprises a compound of formula (1): wherein R¹, R² and R³, which may be the same or different, is each a hydrogen atom or a C₁₋₆ alkyl, C₁₋₃alkoxyC₁₋₃alkyl, -CO₂H, -SO₃H, -PO₃H₂ or group (where R⁴ is a hydrogen atom, a C₁₋₆ alkyl or C₆₋₁₂ aryl group); L is a covalent bond or a linker group comprising an optionally substituted straight or branched C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene hydrocarbyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or a C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, C₅₋₈ cycloalkane, C₆₋₁₂ aromatic, or C₅₋₁₀ heteroaromatic groups, wherein the optional substituents are selected from fluorine, chlorine, bromine, or iodine atoms or groups selected from C₁₋₆alkoxy, hydroxy, nitro, -N(R⁶)(R⁷), [where R⁶ is a hydrogen atom or a C₁₋₆alkyl group and R⁷ is a C₁₋₆ alkyl group] and a group of formula -(CH₂) n CON(R⁸)(R⁹) [where n is zero or an integer 1 to 4 inclusive, R⁸ is a hydrogen atom or a C₁₋₆ alkyl group, and R⁹ is a C₁₋₆ alkyl group optionally substituted by one or more halogen atoms, or nitro, amino or hydroxy groups; Z is a hydrogen atom or a reactive functional group capable of reaction with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group, with the proviso that when L is a covalent bond Z is said reactive functional group; or a metal complex and/or salt thereof, coupled to a protein, peptide or carbohydrate. A conjugate compound of formula (2) wherein R¹, R² and R³, which may be the same or different, is each a hydrogen atom or a C₁₋₆ alkyl, C₁₋₃alkoxyC₁₋₃alkyl, -CO₂H, -SO₃H, -PO₃H₂ or group (where R⁴ is a hydrogen atom, a C₁₋₆ alkyl or C₆₋₁₂ aryl group); L is a covalent bond or a linker group comprising an optionally substituted straight or branched C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene hydrocarbyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or a C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, C₅₋₈ cycloalkane, C₆₋₁₂ aromatic, or C₅₋₁₀ heteroaromatic groups, wherein the optional substituents are selected from fluorine, chlorine, bromine, or iodine atoms or groups selected from C₁₋₆alkoxy, hydroxy, nitro, -N(R⁶)(R⁷), [where R⁶ is a hydrogen atom or a C₁₋₆ alkyl group and R⁷ is a C₁₋₆ alkyl group] and a group of formula -(CH₂) n CON(R⁸)(R⁹) [where n is zero or an integer 1 to 4 inclusive, R⁸ is a hydrogen atom or a C₁₋₆alkyl group, and R⁹ is a C₁₋₆ alkyl group optionally substituted by one or more halogen atoms, or nitro, amino or hydroxy groups; Z¹ is the residue of a reactive functional group capable of reaction with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group; W is zero or an integer 1; z is an integer 1 or more; Ab is an antibody; and metal complexes and/or salts thereof. A composition comprising a compound of formula (1) as defined in claim 1 or a metal complex and/or salt thereof together with one or more pharmaceutically acceptable carriers. A composition comprising a compound of formula (2) as defined in claim 7 or a metal complex and/or salt thereof with one or more pharmaceutically acceptable carriers. A process for the preparation of a compound of formula (1) as defined in claim 1 or a metal complex thereof comprising reacting a compound of formula (3) [where L and Z are as defined for the compound of formula (1)] or a metal complex thereof with a reagent R¹CH₂D [where D is a displaceable group and R¹ is as defined for the compound of formula (1)]. A process for the preparation of a conjugate compound of formula (2) as defined in claim 7 comprising reacting a compound of formula (1) as defined in claim 1 with an antibody Ab.

Inventors: MILLICAN THOMAS ANDREW, PARKER DAVID, MILLICAN, THOMAS, ANDREW, PARKER, DAVID
Applicants: CELLTECH THERAPEUTICS LTD, CELLTECH THERAPEUTICS LIMITED
Application year: 1988
Main classification: C07D255
IPC codes: A61K47, A61K49, A61K39, A61P35, A61K31, C07H17, C07D255, C07D401, C07F9